The state of Michigan currently has 9 active clinical trials seeking participants for Rheumatoid Arthritis research studies. These trials are conducted in various cities, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo.
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: AA Medical Research Center - Grand Blanc /ID# 254007, Grand Blanc, Michigan +1 locations
Conditions: Rheumatoid Arthritis
Dynamic Treatment Regiments for Glucocorticoid Tapering
Recruiting
The purpose of this clinical trial is to better understand how people with rheumatoid arthritis (RA) respond to gradual dose reduction, or "tapering", of steroid medications like prednisone. Some people with RA have symptoms when steroid dose is reduced, while others don't. This trial will look at different patient characteristics, including levels of inflammation in the body, differences in the way the brain processes sensory information, and certain hormone levels, to help researchers better u... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan +1 locations
Conditions: Rheumatoid Arthritis
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
Recruiting
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/29/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Rheumatoid Arthritis, Interstitial Lung Disease
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Pandit Rheumatology PC, Okemos, Michigan
Conditions: Rheumatoid Arthritis
RA-PRO PRAGMATIC TRIAL
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: American Arthritis and Rheumatology Associates -Mi PLLC, Okemos, Michigan
Conditions: Rheumatoid Arthritis
Exactech Shoulder Post Market Clinical Follow-up Study
Recruiting
The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.
Gender:
All
Ages:
21 years and above
Trial Updated:
02/23/2024
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty
Recruiting
Evaluation of the performance and safety of the Catalyst CSR Shoulder System with clinical and radiographic results at multiple time points through 24 months postoperatively This study will be a prospective multi-center study conducted in the United States.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Beaumont Hospital Royal Oak, Royal Oak, Michigan
Conditions: Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus, Rheumatoid Arthritis Shoulder
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)
Recruiting
RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/11/2023
Locations: Anaptys Bio Investigative Site 10-134, Grand Blanc, Michigan
Conditions: Rheumatoid Arthritis